-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Oral and Poster Abstracts

Saturday, December 7, 2024

Saturday | Sunday | Monday | top

9:30 AM-11:00 AM

102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire
401. Blood Transfusion: Advancements in Transfusion Science
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Epigenetic and Metabolic Control of Hematopoiesis
508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH
602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies
603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Determinants of Venetoclax Resistance and Response
617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Multi-omic Applications for Disease Evolution and Response to Therapy
628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas
641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment
653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma?
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies
908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care

12:00 PM-1:30 PM

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease
322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Humoral Coagulation Factors: Venous Thrombosis and Beyond
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP
711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies
802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care

2:00 PM-3:30 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets and Endothelium in Thrombotic Disorders
503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms
603. Lymphoid Oncogenesis: Basic: Molecular Insights into Acute Lymphoblastic Leukemias
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML
617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML
619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond
621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Targets in Aggressive Lymphomas
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Therapies for Mantle Cell Lymphoma
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Personalized and Molecular Approaches in Myeloproliferative Neoplasms: Risk Stratification and Therapeutic Implications
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes
653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies
701. Experimental Transplantation: Basic and Translational: GVHD, Mucosal Immunology and the Microbiome
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Adult Patients
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: AI Approaches to Drug Development, Classification and Outcomes
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!
907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple Myeloma

4:00 PM-5:30 PM

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Tools and Biomarkers for Improving Sickle Cell Disease Treatments
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis in Pregnancy and Childhood
508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies
622. Lymphomas: Translational – Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma
636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders
653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions
702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Monitoring, Understanding and Optimizing GVHD Interventions
902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments
904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Determinants of Health Equity Across the Spectrum
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations
908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies

5:30 PM-7:30 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I
102. Iron Homeostasis and Biology: Poster I
112. Thalassemia and Globin Gene Regulation: Poster I
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I
201. Granulocytes, Monocytes, and Macrophages: Poster I
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I
301. Platelets and Megakaryocytes: Basic and Translational: Poster I
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
321. Coagulation and Fibrinolysis: Basic and Translational: Poster I
322. Hemophilia A and B: Clinical and Epidemiological: Poster I
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I
401. Blood Transfusion: Poster I
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I
506. Bone Marrow Microenvironment: Poster I
508. Bone Marrow Failure: Acquired: Poster I
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I
602. Myeloid Oncogenesis: Basic: Poster I
603. Lymphoid Oncogenesis: Basic: Poster I
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I
619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I
621. Lymphomas: Translational – Molecular and Genetic: Poster I
622. Lymphomas: Translational – Non-Genetic: Poster I
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I
626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
627. Aggressive Lymphomas: Pharmacologic Therapies: Poster I
628. Aggressive Lymphomas: Cellular Therapies: Poster I
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
636. Myelodysplastic Syndromes: Basic and Translational: Poster I
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I
641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
653. Multiple Myeloma: Clinical and Epidemiological: Poster I
654. Multiple Myeloma: Pharmacologic Therapies: Poster I
655. Multiple Myeloma: Cellular Therapies: Poster I
701. Experimental Transplantation: Basic and Translational: Poster I
702. CAR-T Cell Therapies: Basic and Translational: Poster I
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
801. Gene Therapies: Poster I
802. Chemical Biology and Experimental Therapeutics: Poster I
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I
900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I
902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I
904. Outcomes Research: Hemoglobinopathies: Poster I
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
907. Outcomes Research: Plasma Cell Disorders: Poster I
908. Outcomes Research: Myeloid Malignancies: Poster I
909. Education, Communication, and Workforce: Poster I
TiPs 1 Poster Session 1 (14 abstracts)
TiPs 2 Poster Session 1 (55 abstracts)
TiPs 3 Poster Session 1 (35 abstracts)

Sunday, December 8, 2024

Saturday | Sunday | Monday | top

9:30 AM-11:00 AM

112. Thalassemia and Globin Gene Regulation: We're Going to Catch a Big One: Towards Targeted Therapies in Thalassemia
201. Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia
301. Platelets and Megakaryocytes: Basic and Translational: Megakarocyte and Platelet Biology: From Formation to Function
321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism, Differentiation and Inflammation
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes
621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas
624. Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas
626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma
632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice
634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents
653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice
654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA
702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation
801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside
900. Health Services and Quality Improvement: Hemoglobinopathies: Navigating and Optimizing Healthcare Systems
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma
908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity

12:00 PM-1:30 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Regulation of Erythropoiesis
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Improving Outcomes in Sickle Cell Disease Around the World
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes
506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Normal Hematopoiesis
624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy
626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas
627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies
723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases
900. Health Services and Quality Improvement: Hemoglobinopathies: Empowering Choices: Navigating Shared Decision-Making for Patient-Centric Care
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies
909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients

4:30 PM-6:00 PM

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications – Lessons from Pre-clinical Models
602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL
618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis
622. Lymphomas: Translational – Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses
626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma
654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis
907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes

6:00 PM-8:00 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II
102. Iron Homeostasis and Biology: Poster II
112. Thalassemia and Globin Gene Regulation: Poster II
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II
201. Granulocytes, Monocytes, and Macrophages: Poster II
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II
301. Platelets and Megakaryocytes: Basic and Translational: Poster II
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
321. Coagulation and Fibrinolysis: Basic and Translational: Poster II
322. Hemophilia A and B: Clinical and Epidemiological: Poster II
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
401. Blood Transfusion: Poster II
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II
506. Bone Marrow Microenvironment: Poster II
508. Bone Marrow Failure: Acquired: Poster II
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II
602. Myeloid Oncogenesis: Basic: Poster II
603. Lymphoid Oncogenesis: Basic: Poster II
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II
619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster II
621. Lymphomas: Translational – Molecular and Genetic: Poster II
622. Lymphomas: Translational – Non-Genetic: Poster II
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II
626. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
627. Aggressive Lymphomas: Pharmacologic Therapies: Poster II
628. Aggressive Lymphomas: Cellular Therapies: Poster II
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
636. Myelodysplastic Syndromes: Basic and Translational: Poster II
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
653. Multiple Myeloma: Clinical and Epidemiological: Poster II
654. Multiple Myeloma: Pharmacologic Therapies: Poster II
655. Multiple Myeloma: Cellular Therapies: Poster II
701. Experimental Transplantation: Basic and Translational: Poster II
702. CAR-T Cell Therapies: Basic and Translational: Poster II
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
801. Gene Therapies: Poster II
802. Chemical Biology and Experimental Therapeutics: Poster II
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II
900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II
904. Outcomes Research: Hemoglobinopathies: Poster II
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
907. Outcomes Research: Plasma Cell Disorders: Poster II
908. Outcomes Research: Myeloid Malignancies: Poster II
909. Education, Communication, and Workforce: Poster II

Monday, December 9, 2024

Saturday | Sunday | Monday | top

10:30 AM-12:00 PM

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP
322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML
621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes
641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma
654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant
902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials
903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases

2:45 PM-4:15 PM

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: The Effects of Sickle Cell Disease on Organ Function
201. Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis: Models, Risk Factors, and Outcomes
506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell Diseases
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML
618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment
621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia
627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes
636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis
653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse
701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity
702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies
723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival
907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies

4:30 PM-6:00 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease
503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences
602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies
617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World
622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?
627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM
654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma
655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma
702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Avoiding GVHD and Improving Outcomes
723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse
801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs
904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease

6:00 PM-8:00 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III
102. Iron Homeostasis and Biology: Poster III
112. Thalassemia and Globin Gene Regulation: Poster III
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III
201. Granulocytes, Monocytes, and Macrophages: Poster III
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III
301. Platelets and Megakaryocytes: Basic and Translational: Poster III
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
321. Coagulation and Fibrinolysis: Basic and Translational: Poster III
322. Hemophilia A and B: Clinical and Epidemiological: Poster III
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
401. Blood Transfusion: Poster III
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III
506. Bone Marrow Microenvironment: Poster III
508. Bone Marrow Failure: Acquired: Poster III
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III
602. Myeloid Oncogenesis: Basic: Poster III
603. Lymphoid Oncogenesis: Basic: Poster III
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III
621. Lymphomas: Translational – Molecular and Genetic: Poster III
622. Lymphomas: Translational – Non-Genetic: Poster III
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III
628. Aggressive Lymphomas: Cellular Therapies: Poster III
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
636. Myelodysplastic Syndromes: Basic and Translational: Poster III
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
653. Multiple Myeloma: Clinical and Epidemiological: Poster III
654. Multiple Myeloma: Pharmacologic Therapies: Poster III
655. Multiple Myeloma: Cellular Therapies: Poster III
701. Experimental Transplantation: Basic and Translational: Poster III
702. CAR-T Cell Therapies: Basic and Translational: Poster III
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
801. Gene Therapies: Poster III
802. Chemical Biology and Experimental Therapeutics: Poster III
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III
900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III
904. Outcomes Research: Hemoglobinopathies: Poster III
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
907. Outcomes Research: Plasma Cell Disorders: Poster III
908. Outcomes Research: Myeloid Malignancies: Poster III
909. Education, Communication, and Workforce: Poster III